Adjuvanted vaccines against influenza in the elderly

Abstract

Influenza is an important public health issue, especially with the aging of the population, since the most serious consequences of the illness affect the elderly. Between 1979 and 2001, approximately 41000 annual deaths have been attributed to influenza in the United States (Dushoff, 2005). Annual vaccination is a key strategy employed to combat this illness, and while it is very effective in healthy young adults, it is much less successful in the elderly. The impaired immune system with aging may contribute to this diminished ability of the vaccine to afford protection. Strategies to improve vaccine efficacy, particularly for the aged population, are necessary. One potential strategy is the inclusion of adjuvants in the vaccine formulations to enhance the immune response. Adjuvants have been shown to improve antibody production, allow dose-sparing, and potentially increase cross-reactivity. These benefits are important in combating both seasonal influenza and pandemic influenza, as current seasonal vaccine effectiveness depends on close matching to the circulating virus, and fast production of pandemic vaccines are key to their effectiveness. While much is still unknown about adjuvants, especially their mechanisms of action, their potential at improving the efficacy of influenza vaccines has been well recognized, particularly in the elderly.

Keywords

influenza vaccine / elderly / adjuvant

References

[1] Andrews N, Waight P, Yung C F, Miller E (2011). Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England. J Infect Dis, 203(1): 32–39

[2] Banzhoff A, Gasparini R, Laghi-Pasini F, Staniscia T, Durando P, Montomoli E, Capecchi P L, di Giovanni P, Sticchi L, Gentile C, Hilbert A, Brauer V, Tilman S, Podda A (2009). MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS ONE, 4(2): e4384

[3] Beigel J H, Voell J, Huang C Y, Burbelo P D, Lane H C (2009). Safety and immunogenicity of multiple and higher doses of an inactivated influenza A/H5N1 vaccine. J Infect Dis, 200(4): 501–508

[4] Bernstein E, Kaye D, Abrutyn E, Gross P, Dorfman M, Murasko D M (1999). Immune response to influenza vaccination in a large healthy elderly population. Vaccine, 17(1): 82–94

[5] Camilloni B, Neri M, Lepri E, Basileo M, Sigismondi N, Puzelli S, Donatelli I, Iorio A M (2010). An influenza B outbreak during the 2007/2008 winter among appropriately immunized elderly people living in a nursing home. Vaccine, 28(47): 7536–7541

[6] Chan T C, Hung I F, Luk J K, Shea Y F, Chan F H, Woo P C, Chu L W (2011). Efficacy of dual vaccination of pandemic H1N1 2009 influenza and seasonal influenza on institutionalized elderly: a one-year prospective cohort study. Vaccine, 29(44): 7773–7778

[7] Cheong H J, Song J Y, Heo J Y, Noh J Y, Choi W S, Park D W, Wie S H, Kim W J (2011). Immunogenicity and safety of the influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted vaccine. Clin Vaccine Immunol, 18(8): 1358–1364

[8] de Bruijn I A, Nauta J, Gerez L, Palache A M (2006). The virosomal influenza vaccine Invivac: immunogenicity and tolerability compared to an adjuvanted influenza vaccine (Fluad in elderly subjects. Vaccine, 24(44-46): 6629–6631

[9] Deans G D, Stiver H G, McElhaney J E (2010). Influenza vaccines provide diminished protection but are cost-saving in older adults. J Intern Med, 267(2): 220–227

[10] Dushoff J (2005). Assessing influenza-related mortality: comment on Zucs et al. Emerg Themes Epidemiol, 2(1): 7

[11] Fragapane E, Gasparini R, Schioppa F, Laghi-Pasini F, Montomoli E, Banzhoff A (2010). A heterologous MF59-adjuvanted H5N1 prepandemic influenza booster vaccine induces a robust, cross-reactive immune response in adults and the elderly. Clin Vaccine Immunol, 17(11): 1817–1819

[12] Gasparini R, Schioppa F, Lattanzi M, Barone M, Casula D, Pellegrini M, Veitch K, Gaitatzis N (2010). Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria) in adult and elderly subjects. Int J Clin Pract, 64(4): 432–438

[13] Govaert T M, Thijs C T, Masurel N, Sprenger M J, Dinant G J, Knottnerus J A (1994). The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA, 272(21): 1661–1665

[14] Khurana S, Verma N, Yewdell J W, Hilbert A K, Castellino F, Lattanzi M, Del Giudice G, Rappuoli R, Golding H (2011). MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med, 3(85): 85ra48

[15] Langley J M, Risi G, Caldwell M, Gilderman L, Berwald B, Fogarty C, Poling T, Riff D, Baron M, Frenette L, Sheldon E, Collins H, Shepard M, Dionne M, Brune D, Ferguson L, Vaughn D, Li P, Fries L (2011). Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study. J Infect Dis, 203(12): 1729–1738

[16] Lee B Y, Ercius A K, Smith K J (2009). A predictive model of the economic effects of an influenza vaccine adjuvant for the older adult (age 65 and over) population. Vaccine, 27(16): 2251–2257

[17] Madhun A S, Akselsen P E, Sjursen H, Pedersen G, Svindland S, Nøstbakken J K, Nilsen M, Mohn K, Jul-Larsen A, Smith I, Major D, Wood J, Cox R J (2010). An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers. Vaccine, 29(2): 266–273

[18] McElhaney J E, Dutz J P (2008). Better influenza vaccines for older people: what will it take? J Infect Dis, 198(5): 632–634

[19] McElhaney J E, Effros R B (2009). Immunosenescence: what does it mean to health outcomes in older adults? Curr Opin Immunol, 21(4): 418–424

[20] McKee A S, MacLeod M K, Kappler J W, Marrack P (2010). Immune mechanisms of protection: can adjuvants rise to the challenge? BMC Biol, 8(1): 37

[21] McKee A S, Munks M W, Marrack P (2007). How do adjuvants work? Important considerations for new generation adjuvants. Immunity, 27(5): 687–690

[22] Neafsey P J, Tyler C (2005). Efficacy of influenza vaccine in the elderly. Home Healthc Nurse, 23(10): 640–641

[23] O’Hagan D T, Rappuoli R, De Gregorio E, Tsai T, Del Giudice G (2011). MF59 adjuvant: the best insurance against influenza strain diversity. Expert Rev Vaccines, 10(4): 447–462

[24] Phillips C J, Matyas G R, Hansen C J, Alving C R, Smith T C, Ryan M A (2009). Antibodies to squalene in US Navy Persian Gulf War veterans with chronic multisymptom illness. Vaccine, 27(29): 3921–3926

[25] Podda A (2001). The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine, 19(17-19): 2673–2680

[26] Puig-Barberà J, Diez-Domingo J, Pérez Hoyos S, Belenguer Varea A, González Vidal D (2004). Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age. Vaccine, 23(3): 283–289

[27] Roman F, Vaman T, Kafeja F, Hanon E, Van Damme P (2010). AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. Clin Infect Dis, 51(6): 668–677

[28] Ruf B R, Colberg K, Frick M, Preusche A (2004). Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly. Infection, 32(4): 191–198

[29] Thompson W W, Moore M R, Weintraub E, Cheng P Y, Jin X, Bridges C B, Bresee J S, Shay D K (2009). Estimating influenza-associated deaths in the United States. Am J Public Health, 99(S2 Suppl 2): S225–S230

[30] Treanor J J, Campbell J D, Zangwill K M, Rowe T, Wolff M (2006). Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med, 354(13): 1343–1351

[31] Vajo Z (2011). The seasonal influenza vaccine Agriflu(®). Expert Rev Vaccines, 10(11): 1513–1517

[32] Vesikari T, Groth N, Karvonen A, Borkowski A, Pellegrini M (2009). MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. Vaccine, 27(45): 6291–6295

Acknowledgments

We thank Jack Ju for his assistance in preparing this manuscript.

RIGHTS & PERMISSIONS

2014 Higher Education Press and Springer-Verlag Berlin Heidelberg